Novel ruthenium(II) cyclopentadienyl thiosemicarbazone compounds with antiproliferative activity on pathogenic trypanosomatid parasites
Author
dc.contributor.author
Fernández, Mariana
Author
dc.contributor.author
Rodríguez Arce, Esteban
Author
dc.contributor.author
Sarniguet, Cynthia
Author
dc.contributor.author
Morais, Tânia S.
Author
dc.contributor.author
Tomaz, Ana Isabel
Author
dc.contributor.author
Olea Azar, Claudio
Author
dc.contributor.author
Figueroa, Roberto
Author
dc.contributor.author
Maya Arango, Juan
Author
dc.contributor.author
Medeiros, Andrea
Author
dc.contributor.author
Comini, Marcelo
Author
dc.contributor.author
Garcia, M. Helena
Author
dc.contributor.author
Otero, Lucía
Author
dc.contributor.author
Gambino, Dinorah
Admission date
dc.date.accessioned
2016-03-07T13:05:55Z
Available date
dc.date.available
2016-03-07T13:05:55Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Journal of Inorganic Biochemistry 153 (2015) 306–314
en_US
Identifier
dc.identifier.other
DOI: 10.1016/j.jinorgbio.2015.06.018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/136958
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Searching for new prospective antitrypanosomal agents, three novel Ru(II)-cyclopentadienyl compounds, [Ru(eta(5)-C5H5)(PPh3)L], with HL = bioactive 5-nitrofuryl containing thiosemicarbazones were synthesized and characterized in the solid state and in solution. The compounds were evaluated in vitro on the blood circulating trypomastigote form of Trypanosoma cruzi (Dm28c strain), the infective form of Trypanosoma brucei brucei (strain 427) and on J774 murine macrophages and human-derived EA.hy926 endothelial cells. The compounds were active against both parasites with IC50 values in the micromolar or submicromolar range. Interestingly, they are much more active on T. cruzi than previously developed Ru(II) classical and organometallic compounds with the same bioactive ligands. The new compounds showed moderate to very good selectivity towards the parasites in respect to mammalian cells. The global results point at [RuCp(PPh3)L2] (12 = N-methyl derivative of 5-nitrofuryl containing thiosemicarbazone and Cp = cyclopentadienyl) as the most promising compound for further developments (IC50 T. cruzi = 0.41 mu M; IC50 T. brucei brucei = 3.5 mu M). Moreover, this compound shows excellent selectivity towards T. cruzi (SI > 49) and good selectivity towards T. brucei brucei (SI > 6). In order to get insight into the mechanism of antiparasitic action, the intracellular free radical production capacity of the new compounds was assessed by ESR. DMPO (5,5-dimethyl-1-pirroline-N-oxide) spin adducts related to the bioreduction of the complexes and to redox cycling processes were characterized. In addition, DNA competitive binding studies with ethidium bromide by fluorescence measurements showed that the compounds interact with this biomolecule.